How should we treat a patient who has a molecular relapse after transplant?

During the 8th Annual Meeting of the Society of Hematologic Oncology (SOHO), the ALL Hub spoke to Lori Muffly, Stanford University, Stanford, US. We asked, How should we treat a patient who has a molecular relapse after transplant?

Muffly begins by defining what a molecular relapse is, and how it can be monitored and evaluated. She goes on to discuss therapy options for molecular relapse post allogeneic stem cell transplantation, such as tyrosine kinase inhibitors, CAR T-cells, and bispecific antibodies according to Philadelphia chromosome (Ph) status and ALL lineages. Finally, Muffly talks about a recent publication looking at outcomes of secondary transplants.